RELMADA THERAPEUTICS, INC.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a clinical-stage biotechnology company focused on developing novel pharmaceutical candidates to address unmet medical needs in oncology and neurological disorders. The company maintains its principal operations and development capabilities in the United States and operates… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What RELMADA THERAPEUTICS, INC. does
In the company’s own words
Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a clinical-stage biotechnology company focused on developing novel pharmaceutical candidates to address unmet medical needs in oncology and neurological disorders. The company maintains its principal operations and development capabilities in the United States and operates as a publicly traded entity on the NASDAQ capital market.
The company's current development pipeline centers on two primary product candidates. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel designed for the treatment of non-muscle-invasive bladder cancer. The product enables single administration in less than five minutes while delivering sustained, localized chemotherapy for up to ten days, addressing limitations of conventional sequential drug delivery methods. Relmada is developing NDV-01 for two separate indications: high-risk, second-line BCG-unresponsive non-muscle-invasive bladder cancer and intermediate-risk patients in the adjuvant setting. The company's Phase 2 data demonstrated a 95 percent complete response rate with favorable safety profiles across 48 enrolled patients.
The company's second lead candidate, sepranolone, is a novel neurosteroid designed to normalize GABAA receptor activity for potential treatment of Prader-Willi syndrome, Tourette Syndrome, essential tremor, and other disorders related to excessive GABAergic activity. Phase 2a data demonstrated competitive tic reduction and improved quality of life metrics in Tourette Syndrome patients with no serious adverse events reported.
Relmada substantially restructured its development portfolio in late 2024 and early 2025, terminating its esmethadone program following clinical setbacks and discontinuing its psilocybin development efforts. The company acquired sepranolone from Asarina Pharma AB in February 2025 and in-licensed NDV-01 from Trigone Pharma Ltd. in March 2025, representing a strategic pivot toward acquiring clinical-stage candidates with established development pathways.
The company maintains an intellectual property portfolio comprising more than forty issued patents and pending applications related to sepranolone and more than ten issued patents related to NDV-01, with potential coverage extending beyond 2038. Relmada has not generated commercial revenues and does not anticipate doing so in the foreseeable future, as none of its product candidates has received regulatory approval for sale in any jurisdiction.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CORAL GABLES, FL
- Fiscal year end
- December
- CIK
- 1553643
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns RELMADA THERAPEUTICS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · RELMADA THERAPEUTICS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do RELMADA THERAPEUTICS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of RELMADA THERAPEUTICS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in RELMADA THERAPEUTICS, INC.'s last four quarterly filings that the numbers alone won't show?”